[go: up one dir, main page]

WO1992008985A3 - Procede de dosage de proteines de liaison d'hormones immunofonctionnel induit par ligands - Google Patents

Procede de dosage de proteines de liaison d'hormones immunofonctionnel induit par ligands Download PDF

Info

Publication number
WO1992008985A3
WO1992008985A3 PCT/US1991/008664 US9108664W WO9208985A3 WO 1992008985 A3 WO1992008985 A3 WO 1992008985A3 US 9108664 W US9108664 W US 9108664W WO 9208985 A3 WO9208985 A3 WO 9208985A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding protein
hormone
ligand
bound
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/008664
Other languages
English (en)
Other versions
WO1992008985A2 (fr
Inventor
Lena Mariana Susann Carlsson
Ross Graham Clark
Wai Lee Tan Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP4501539A priority Critical patent/JP2977280B2/ja
Priority to AU91067/91A priority patent/AU657109B2/en
Priority to DK99123825T priority patent/DK0995445T3/da
Priority to EP92901281A priority patent/EP0558647B1/fr
Priority to HK98106559A priority patent/HK1007351A1/en
Priority to CA002093927A priority patent/CA2093927C/fr
Priority to DE69119911T priority patent/DE69119911T2/de
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of WO1992008985A2 publication Critical patent/WO1992008985A2/fr
Publication of WO1992008985A3 publication Critical patent/WO1992008985A3/fr
Anticipated expiration legal-status Critical
Priority to US08/441,357 priority patent/US5593844A/en
Priority to GR960401874T priority patent/GR3020505T3/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)

Abstract

Procédé de dosage immunofonctionnel induit par ligands (LIFA) permettant de détecter la présence et la concentration de protéines de liaison d'hormones polypeptidiques consistant à capturer la protéine de liaison à l'aide d'un premier anticorps lié à une phase solide, à saturer la protéine de liaison d'hormones avec l'hormone polypeptidique de ligand, et à détecter l'hormone polypeptidique de ligands liée à l'aide d'un second anticorps marqué de manière détectable et spécifique de l'hormone polypeptidique de ligands. En l'absence d'hormone polypeptidique de saturation ajoutée, le LIFA mesure la quantité de protéines de liaison d'hormones liées à l'hormone polypeptidique de ligands endogènes . Un dosage de protéines de liaison d'hormones de croissance illustre le procédé de l'invention. Les résultats du dosage LIFA indiquent qu'une protéine de liaison accrue augmente sensiblement l'activité de l'hormone de croissance. L'invention concerne également des procédés d'utilisation ainsi que des formulations de protéine de liaison d'hormone de croissance, d'hormone de croissance, de facteur-I de croissance analogue à l'insuline et de protéine de liaison de facteur de croissance analogue à l'insuline.
PCT/US1991/008664 1990-11-19 1991-11-19 Procede de dosage de proteines de liaison d'hormones immunofonctionnel induit par ligands Ceased WO1992008985A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU91067/91A AU657109B2 (en) 1990-11-19 1991-11-19 Ligand-mediated immunofunctional hormone binding protein assay method
DK99123825T DK0995445T3 (da) 1990-11-19 1991-11-19 Anvendelse af IGF-1 alene eller kombineret med væksthormon til stimulering af vækst
EP92901281A EP0558647B1 (fr) 1990-11-19 1991-11-19 Procede de dosage de proteines de liaison d'hormones immunofonctionnel induit par ligands
HK98106559A HK1007351A1 (en) 1990-11-19 1991-11-19 Ligand-mediated immunofunctional hormone binding protein assay method
CA002093927A CA2093927C (fr) 1990-11-19 1991-11-19 Methode immunofonctionnelle de dosage a mediation par un ligand d'une proteine liant une hormone
JP4501539A JP2977280B2 (ja) 1990-11-19 1991-11-19 リガンド媒介免疫機能的ホルモン結合タンパク質検定法
DE69119911T DE69119911T2 (de) 1990-11-19 1991-11-19 Durch den liganden vermitteltes immunofunktionelles verfahren zur bestimmung hormonbindender proteine
US08/441,357 US5593844A (en) 1990-11-19 1995-05-15 Ligand-mediated immunofunctional hormone binding protein assay method
GR960401874T GR3020505T3 (en) 1990-11-19 1996-07-10 Ligand-mediated immunofunctional hormone binding protein assay method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US615,538 1990-11-19
US07/615,538 US5210017A (en) 1990-11-19 1990-11-19 Ligand-mediated immunofunctional hormone binding protein assay method

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US07/615,538 Continuation-In-Part US5210017A (en) 1990-11-19 1990-11-19 Ligand-mediated immunofunctional hormone binding protein assay method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US40809495A Continuation 1990-11-19 1995-03-21

Publications (2)

Publication Number Publication Date
WO1992008985A2 WO1992008985A2 (fr) 1992-05-29
WO1992008985A3 true WO1992008985A3 (fr) 1992-10-29

Family

ID=24465822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/008664 Ceased WO1992008985A2 (fr) 1990-11-19 1991-11-19 Procede de dosage de proteines de liaison d'hormones immunofonctionnel induit par ligands

Country Status (12)

Country Link
US (1) US5210017A (fr)
EP (3) EP0995445B1 (fr)
JP (2) JP2977280B2 (fr)
AT (3) ATE425764T1 (fr)
AU (1) AU657109B2 (fr)
CA (1) CA2093927C (fr)
DE (3) DE69119911T2 (fr)
DK (3) DK0995445T3 (fr)
ES (3) ES2090598T3 (fr)
GR (1) GR3020505T3 (fr)
HK (1) HK1007351A1 (fr)
WO (1) WO1992008985A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283273B2 (en) 1995-07-27 2016-03-15 Genentech, Inc. Protein formulation
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866350A (en) * 1985-03-19 1999-02-02 Helen Hwai-An Lee Method for the immunological determination of a biological material in a sample
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US6326154B1 (en) * 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5464757A (en) * 1991-01-15 1995-11-07 The Salk Institute For Biological Studies DNA encoding CRF binding protein
CA2489978A1 (fr) * 1992-07-31 1994-02-17 Genentech, Inc. Preparation aqueuse contenant l'hormone de croissance humaine
US6087188A (en) * 1992-11-13 2000-07-11 Alk A/S Two-site immunoassay for an antibody with chemiluminescent label and biotin bound ligand
WO1995000649A1 (fr) * 1993-06-25 1995-01-05 Smithkline Beecham Plc Phospholipase a2 associee a une lipoproteine, inhibiteurs de cette phospholipase et son utilisation a des fins diagnostiques et therapeutiques
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
DE60016560T2 (de) * 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
DK1282437T3 (da) * 2000-05-16 2008-06-30 Genentech Inc Behandling af brusklidelser
US7108993B2 (en) * 2002-07-19 2006-09-19 Bayer Healthcare Llc Use of dual conjugated labels in the elimination of serum interference in immunochromatographic assays
SE0300959D0 (sv) * 2002-12-19 2003-04-02 Pharmacia Ab Methods for predicting therapeutic response to agents acting on the growth hormone receptor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
EP2274978B1 (fr) 2003-09-12 2015-05-20 Tercica, Inc. Méthodes de traitement de la déficience du facteur de croissance de type insuline 1 (IGF-1)
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US20070045902A1 (en) 2004-07-13 2007-03-01 Brauker James H Analyte sensor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003357A1 (fr) * 1984-01-30 1985-08-01 Icrf Patents Ltd. Ameliorations relatives aux facteurs de croissance
WO1988009818A2 (fr) * 1987-06-12 1988-12-15 Genentech Inc Recepteur d'hormone de croissance
DD263537A1 (de) * 1987-09-01 1989-01-04 Akad Wissenschaften Ddr Verfahren zur herstellung von monoklonalen antikoerpern gegen humanes wachstumshormon
WO1989007271A1 (fr) * 1988-01-28 1989-08-10 E.I. Du Pont De Nemours And Company Immunoanalyses a l'aide d'anticorps monoclonaux dresses contre des proteines de liaison naturelles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE263537C (fr) *
NL7501215A (nl) * 1975-02-01 1976-08-03 Akzo Nv Methode voor het aantonen en bepalen van een antigeen of antilichaam.
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4476228A (en) * 1982-11-08 1984-10-09 Abbott Laboratories Determination of unsaturated thyroxine binding protein sites using fluorescence polarization techniques
US4622293A (en) * 1983-07-05 1986-11-11 Miles Laboratories, Inc. Iodothyronine immunoassays employing HMS as TBP blocking agent
US4594327A (en) * 1983-11-02 1986-06-10 Syntex (U.S.A.) Inc. Assay method for whole blood samples
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4956302A (en) * 1987-09-11 1990-09-11 Abbott Laboratories Lateral flow chromatographic binding assay device
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
JPH03504597A (ja) * 1988-04-12 1991-10-09 シナージェン，インコーポレーテッド インスリン様成長因子活性の強化および阻害方法
CA1341598C (fr) * 1988-07-15 2009-09-29 Central Sydney Area Health Service Sous-unite labile en milieu acide d'un complexe proteique se liant a un factuer de croissance insulinuide
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
WO1990015142A1 (fr) * 1989-06-09 1990-12-13 Gropep Pty. Ltd. Proteines de fusion pour hormones de croissance
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003357A1 (fr) * 1984-01-30 1985-08-01 Icrf Patents Ltd. Ameliorations relatives aux facteurs de croissance
WO1988009818A2 (fr) * 1987-06-12 1988-12-15 Genentech Inc Recepteur d'hormone de croissance
DD263537A1 (de) * 1987-09-01 1989-01-04 Akad Wissenschaften Ddr Verfahren zur herstellung von monoklonalen antikoerpern gegen humanes wachstumshormon
WO1989007271A1 (fr) * 1988-01-28 1989-08-10 E.I. Du Pont De Nemours And Company Immunoanalyses a l'aide d'anticorps monoclonaux dresses contre des proteines de liaison naturelles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Database WPIL, Derwent Publications, (London, GB) Accession no. 88-363994, week 8851, & JP, A, 63273496 (SUMITOMO SEIYAKU K.K.) 10 November 1988, see the abstract *
Journal of Clinical Endocrinology and Metabolism, volume 73, no. 6, The Endocrine Society (US) L.M.S. Carlsson et al.: "Ligand-mediated immunofunctional assay for quantitation of growth hormone-binding protein in human blood", pages 1216-1221 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283273B2 (en) 1995-07-27 2016-03-15 Genentech, Inc. Protein formulation
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor

Also Published As

Publication number Publication date
ATE425764T1 (de) 2009-04-15
DK0995445T3 (da) 2009-07-06
CA2093927A1 (fr) 1992-05-20
EP0681842A2 (fr) 1995-11-15
EP0681842B1 (fr) 2002-02-13
DE69132931T2 (de) 2002-11-28
ES2171478T3 (es) 2002-09-16
EP0558647B1 (fr) 1996-05-29
DE69133614D1 (de) 2009-04-30
ES2324322T3 (es) 2009-08-04
AU9106791A (en) 1992-06-11
CA2093927C (fr) 2000-07-18
EP0995445A3 (fr) 2004-01-07
GR3020505T3 (en) 1996-10-31
EP0995445B1 (fr) 2009-03-18
JP2977280B2 (ja) 1999-11-15
EP0681842A3 (fr) 1998-06-10
DE69132931D1 (de) 2002-03-21
ATE138739T1 (de) 1996-06-15
WO1992008985A2 (fr) 1992-05-29
DE69119911D1 (de) 1996-07-04
HK1007351A1 (en) 1999-04-09
ATE213165T1 (de) 2002-02-15
DK0681842T3 (da) 2002-06-03
JP3159966B2 (ja) 2001-04-23
JPH06502724A (ja) 1994-03-24
EP0558647A1 (fr) 1993-09-08
US5210017A (en) 1993-05-11
EP0995445A2 (fr) 2000-04-26
ES2090598T3 (es) 1996-10-16
DE69119911T2 (de) 1996-11-21
JPH11346765A (ja) 1999-12-21
DK0558647T3 (da) 1996-08-19
AU657109B2 (en) 1995-03-02

Similar Documents

Publication Publication Date Title
EP0995445A3 (fr) Procédé de dosage de protéines de liaison d'hormones immunofonctionnel induit par ligands
PL393286A1 (pl) Rozpuszczalny receptor BR43x2 i sposoby jego zastosowania
Jonas et al. The human placenta contains two distinct binding and immunoreactive species of insulin-like growth factor-I receptors.
AU8866291A (en) Assay for glycated blood proteins
NZ512762A (en) Method of identifying N-terminal proBNP (brain natriuretic peptide) using antibodies
ES8800435A1 (es) Un metodo de inmunoensayo.
AU2002223044A1 (en) Kit and method for detecting the esm-1 protein
CA2291983A1 (fr) Methode immunofonctionnelle de dosage a mediation par un ligand d'une proteine liant une hormone
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2093927

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992901281

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992901281

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992901281

Country of ref document: EP